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This review focuses on developments after 2008, when the topic was last reviewed by
the author. Pertinent publications were found by medline searches and in the author’s per-
sonal data base. Prevention of atrial ﬁbrillation (AF) was investigated in a number of trials,
sparked by one positive report on the effects of eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), considerations of upstream therapy, data from electrophysiologic
laboratories and animal experiments. If EPA+DHA prevent postoperative AF, the effect
is probably smaller than initially expected. The same is probably true for maintenance of
sinus rhythm after cardioversion and for new-onset AF. Larger trials are currently ongoing.
Prevention of ventricular arrhythmias was studied in carriers of an implanted cardioverter-
deﬁbrillator, with no clear results. This might have been due to a broad deﬁnition of the
primary endpoint, including any ventricular arrhythmia and any action of the device. Epi-
demiologic studies support the contention that high levels of EPA+DHA prevent sudden
cardiac death (SCD). However, since SCD is a rare occurrence, it is difﬁcult to conduct an
adequately powered trial. In patients with congestive heart failure, EPA+DHA reduced
total mortality and rehospitalizations, but not SCD or presumed arrhythmic death. Of three
trials in patients after a myocardial infarction, two were inadequately powered, and in one,
the dose might have been too low.Taken together, while epidemiologic studies support an
inverse relation between EPA+DHA and occurrence of SCD or arrhythmic death, demon-
strating this effect in intervention trials remained elusive so far. A pro-arrhythmic effect of
EPA+DHA has not been seen in intervention studies, and results of epidemiologic and
animal studies also rather argue against such an effect. A different, and probably more
productive, perspective is provided by a standardized analytical assessment of a person’s
status in EPA+DHA by use of the omega-3 index, EPA+DHA in red cell fatty acids. In
populations with a high omega-3 index, SCD is rare. Intervention trials can become more
effective by including a low omega-3 index into the inclusion criteria, thus creating a study
population more likely to demonstrate an effect of EPA+DHA. This is especially relevant
in case of rare endpoints, like new-onset AF or SCD.
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INTRODUCTION
The view that the two marine omega-3 fatty acids eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) impact
on cardiac rhythm goes back a number of years, and has been
reviewed by this author in 2008 (von Schacky, 2008). Underly-
ing mechanisms have recently been reviewed (Richardson et al.,
2011). The impression that EPA+DHA are primarily anti-
arrhythmic has been challenged by results of clinical studies,
reporting that EPA and DHA did not reduce sudden cardiac death
(SCD; Rauch et al., 2010). Moreover, in one study, it had been
reported that higher levels of EPA and DHA in red blood cells
Abbreviations: AF, atrial ﬁbrillation; CI, conﬁdence interval; DHA, docosa-
hexaenoic acid; EPA, eicosapentaenoic acid; HR, hazard ratio; ICD, implanted
cardioverter-deﬁbrillator; SCD, sudden cardiac death; VF, ventricular ﬁbrillation;
VT, ventricular tachycardia.
were associated with a higher likelihood of ventricular arrhyth-
mias (Wilhelm et al., 2008). These results are in contrast to
the manifold evidence present already in 2008, indicating anti-
arrhythmic effects of EPA and DHA (von Schacky, 2008). The
present review will highlight recent developments and put them
into perspective.
METHOD
Medline searches were performed with the combination of
“omega-3,” “n−3 fatty acids” “eicosapentaenoic,” or “docosa-
hexaenoic” with “arrhythmia,” and investigations conducted in
humans and fully published in more recent years than 2008 were
selected. Studies on animals were also included, in case animals
were pre-fed with omega-3 fatty acids. In addition, the author’s
personal base of publications was used. Abstracts presented at
scientiﬁc meetings were not included.
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ANIMAL STUDIES
Experiments on ion channels in cultured cells, on cardiac tissue
in vitro, Langendorff preparations of explanted hearts, or using
similar techniques investigating acute effects of EPA and/or DHA
are reviewed elsewhere (De Caterina, 2011; Mozaffarian and Wu,
2011; Richardson et al., 2011; Savelieva et al., 2011). Of note, in
such studies biologically active metabolites of EPA and DHA were
deﬁned,making the developments of more effective compounds a
distinct possibility (e.g., Falck et al., 2011).
CARDIAC RHYTHM
Heart rate and heart rate variability were recorded at rest, during
submaximal exercise, and during a 2-min coronary artery occlu-
sion at rest in dogs with a healed myocardial infarction before and
after 3months supplementation with a ﬁsh oil or corn oil. Fish oil,
but not corn oil reduced heart rate and heart variability at rest, but
not during exercise or during coronary occlusion (Billman and
Harris, 2011).
NEW-ONSET POSTOPERATIVE AF
Dogs were fed a ﬁsh oil-enriched chow (or control) for 3weeks
before excision of the left atrial appendage. Burst pacing induced
atrial ﬁbrillation (AF) only in control dogs, whereas postopera-
tive atrial effective refractory period was prolonged, heart rate was
lower, and heart rate variability higher in the ﬁsh oil-fed dogs. Less
postoperative inﬂammatory reaction was observed in the atria of
ﬁsh oil-fed dogs (Mayyas et al., 2011).
NEW-ONSET AF
After 7 days feeding of a ﬁsh oil or a control chow, dogs were
atrioventricularly paced at 220 bpm for 14 days (feeding was con-
tinued). A third group of dogs was fed a regular chow and
was not paced. Atrial tissue was sampled and analyzed for gene
expression using a quantitative reverse real-time polymerase chain
reaction. Genes related to ﬁbrosis, hypertrophy, and inﬂamma-
tion were found to be down-regulated by the ﬁsh oil supplement
(Ramadeen et al., 2010). More recently, the same group initi-
ated treatment with EPA+DHA 7days after simultaneous atrial
and ventricular pacing was initiated to induce AF (Ramadeen
et al., 2012). After a total of 14 days of pacing, no effects of
EPA+DHA were seen on development of AF, echocardiographic
and histologic parameters, and on expression of ﬁbrosis-related
genes, which was in contrast to the previous study, where dogs
were fed before pacing (Ramadeen et al., 2012). In a similar
study, after 7 days of feeding EPA, rabbits were subjected to ven-
tricular pacing at 400 bpm for 4weeks to induce heart failure
(feeding was continued). One group of control rabbits was not
fed EPA, one group was not paced. Duration of AF after burst
pacing was attenuated in the EPA group, as was atrial ﬁbro-
sis and a number of inﬂammatory parameters (Kitamura et al.,
2011).
Taken together, these animal studies indicate that the propen-
sity develop AF is mitigated by pre-feeding omega-3 fatty acids by
interactions at various levels – from gene expression to refractory
period. However, use of EPA+DHA 7days after initiation of pac-
ing had no effect. No study was found indicating a pro-arrhythmic
effect on the supraventricular level.
VENTRICULAR ARRHYTHMIAS/CELL PREPARATIONS
Infusion of omega-3 fatty acids corrected some, but not all abnor-
malities of ventricular ion channel function induced by omega-3
depletion in rats (Peltier et al., 2009).
VENTRICULAR ARRHYTHMIAS/LANGENDORFF PREPARATIONS
Rats were fed diets enriched in ﬁsh oil, sunﬂower oil, or beef tallow
for 6weeks. The hearts were either subjected to ischemic precondi-
tioning or not. It was found that ischemic preconditioning reduced
ventricular arrhythmias in all dietary groups, but mostly so in the
ﬁsh oil group (Abdukeyum et al., 2008). In another study, rab-
bits were fed ﬁsh oil or a control laboratory chow for 30 days. The
heartswere challengedwith dofetilide, a selective rapidly activating
delayed rectiﬁer potassium current inhibitor with pro-arrhythmic
effects. Dofetilide-induced triangulation, reverse use-dependence,
instability, and dispersion were reduced and torsade de pointes
abolished (Dujardin et al., 2008). Pre-feeding with omega-3 fatty
acids did not suppress the incidence of ventricular reperfusion
arrhythmias after global no-ﬂow ischemia in hearts of female mice
(Huggins et al., 2009). Rats with or without hypertriglyceridemia
were given atorvastatin and/or omega-3 fatty acids for 2months.
Threshold for VF was tested by electrical stimuli. Threshold for
VF was lower in hypertriglyceridemic rats, but was signiﬁcantly
increased by omega-3 fatty acids, an effect found to be related to
an improvement in cell-to-cell junction integrity (Bacova et al.,
2010).
VENTRICULAR ARRHYTHMIAS/WHOLE ANIMAL EXPERIMENTS
Pericardial infusion of DHA reduced infarct size and ventricular
arrhythmias in pigs subjected to experimental myocardial infarc-
tion (Xiao et al., 2008). Cells from explanted hearts from rabbits
or humans with congestive heart failure were superfused with
EPA or DHA. This abolished triggered activity and reduced the
number of delayed afterdepolarizations and calcium aftertran-
sients compared with control and oleic acid (Den Ruijter et al.,
2008). In aged spontaneously hypertensive rats, ﬁsh oil feeding
for 2months suppressed inducible ventricular ﬁbrillations, and
improved other cardiac parameters in comparison to untreated
controls (Mitasíková et al., 2008). Dogswere subjected to an exper-
imental myocardial infarction, and 4weeks later randomized to
receive omega-3 fatty acids or placebo for 3months. Ventricular
function was then assessed in a number of ways, but no differ-
ences were found (Billman et al., 2010). Size of an experimental
infarction was smaller in rats given omega-3 fatty acids than diets
rich in saturated or omega-6 fatty acids (Zeghichi-Hamri et al.,
2010). Male pigs were fed EPA or a control chow for 3weeks, and
then a 90-min myocardial ischemia was induced. EPA attenuated
occurrence of VF, reduced mortality, and attenuated monophasic
action potential duration shortening during ischemia (Tsuburaya
et al., 2011). Very recently, results of experiments in dogs with
healed myocardial infarction, made ischemic by occlusion of the
circumﬂex artery in the last minute of exercise were reported (Bill-
man et al., 2012). The dogs received either a corn oil placebo
or doses of EPA+DHA ranging from 1 to 4 g/day for 3months,
the latter being incorporated into red cell and cardiac tissue fatty
acids. EPA+DHA did not prevent arrhythmias in dogs in which
VF could be induced before treatment started (decreased in 27%
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placebo vs. 24% n−3 PUFA, p = 0.5646) but made dogs in which
VT orVF could not be induced before treatment susceptible (n−3
PUFA 33% vs. placebo 0%, p = 0.0442). The authors concluded
that dietary n−3 PUFAs did not prevent ischemia-inducedVF and
actually increased arrhythmia susceptibility in both non-infarcted
and low-risk post-MI dogs (Billman et al., 2012).
Taken together, pre-feeding omega-3 fatty acids before experi-
mental myocardial infarctions reduced mortality, infarct size and
ventricular arrhythmias. However, 4 weeks after an experimental
myocardial infarction, feeding omega-3 fatty acids did not affect
ventricular function, and reduced VT’s in two, and increased VT’s
in one study. Most studies of Langendorff preparations of hearts
from animals pre-fed with omega-3 fatty acids indicate a reduced
propensity toward ventricular arrhythmias. One study sawno sup-
pression of reperfusion arrhythmias. Taken together, results from
animal studies are not homogeneous, and might depend on the
model studied. In this authors personal opinion, results from ani-
mal studies should have little impact on clinical decisions. Rather,
clinical decisions should be guided by data derived from human
studies, preferably large intervention trials.
STUDIES IN HUMANS
SUPRAVENTRICULAR ARRHYTHMIAS
Aside from epidemiologic observations (Gronroos and Alonso,
2010;Wuet al., 2012),promising results of studies on effects of EPA
and DHA on atrial tissue or cells, and a number of animal models
mentioned above, and more extensively reviewed in Savelieva et al.
(2011), interest in randomized clinical trials was sparked by a trial,
in which EPA and DHA prevented new-onset AF in patients after a
coronary bypass operation (Calò et al., 2005). Supportive evidence
was provided by a small randomized controlled intervention trial
on parameters measured in the electrophysiology laboratory in
a total of 36 patients, demonstrating that a mean treatment of
40 days with 1.8 g/day EPA+DHA in a ﬁsh oil prolonged pul-
monary venous and left atrial effective refractory periods and
decreased susceptibility to initiation AF from within pulmonary
veins (Kumar et al., 2011a). In two follow-up studies from the
same group, using the same approach, it was found that 1.8 g/day
EPA+DHA prolonged atrial refractoriness and reduced vulnera-
bility to inducible AF, and attenuated atrial mechanical stunning
after reversion of atrial arrhythmias to sinus rhythm (Kumar et al.,
2011b,c). While the results just mentioned were promising, they
needed to be scrutinized in trials using occurrence of AF as an
endpoint.
New-onset postoperative AF
For a randomized double-blind single-center study in Germany,
102 patients were recruited before a coronary bypass opera-
tion (Heidt et al., 2009). Throughout the hospital stay, they
were given 1ml/kg body weight/day of an intravenous formu-
lation. In the intervention group of 52 patients, this formu-
lation contained, according to the authors, 10mg of a ﬁsh
oil per 100ml, which, again according to the authors, resulted
in a dose of 100mg ﬁsh oil/kg body weight/day. Accord-
ing to a reference manual, 100ml of this formulation con-
tain between 1.25–2.82 g EPA and 1.44–3.09 g DHA (http://new.
ch.oddb.org/de/drugs/fachinfo/uid/186817). The control group
received a soy-based intravenous formulation, containing 10 g of
soy bean oil per 100ml, resulting in 100mg soy bean oil/kg body
weight/day. Sample size calculationwas basedona30%occurrence
of postoperative AF in the control group and a 20% occurrence
in the intervention group, and testing for signiﬁcance after each
event (but no correction for multiple testing), other assumptions
were not reported. Heart rhythm was monitored continuously on
the intensive care unit. It is not reported, whether all or how many
of the recruited patients were evaluated at study end. According
to table 3 of the publication, 3 days postoperatively, 11 patients
in the control group (according to the authors 11.58%), and
7 patients in the intervention group (according to the authors
7.37%) developed AF. According to the authors, “after the 18th
test, the procedure can be stopped with a probability of error of
0.01.” In the abstract of the publication, the authors state: “Post-
operative AF occurred in 15 patients (according to the authors
30.6%) in the control and in 9 (according to the authors 17.3%)
in the PUFA group (p< 0.05).” In two ﬁgures, a trend toward a
shorter hospital stay for patients in sinus rhythm is depicted, but
in the abstract, the authors state: “After CABG, the PUFA patients
had to be treated in the ICU for a shorter time than the control
patients.” The authors concluded that “perioperative intravenous
infusion of PUFA should be recommended for patients under-
going CABG,” because “PUFA reduces the incidence of AF after
CABG and leads to a shorter stay in the ICU and in hospital.”
The latter conclusion does not appear to be supported by a signif-
icant difference in hospital stays between control and intervention
groups, and the former is based on numbers that are difﬁcult to
comprehend.
For another randomized double-blind single-center study, this
time in the UK, 108 patients were recruited before a coronary
bypass operation (Saravanan et al., 2010). Patients were recruited
1–3weeks preoperatively, and were given either two 1 g capsules
per day of a 85% ﬁsh oil concentrate in the form of an ethyl-
ester (54 patients), or identical capsules containing olive oil as
a placebo (54 patients). Sample size was calculated based on an
expected incidence of postoperative AF of 50% in the placebo
group and a relative risk reduction of 55% by EPA and DHA,
and the usual assumptions (α< 0.05, β= 0.8). Heart rhythm was
monitored continuously with a recorder for 5 days postoperatively,
and episodes of AF>30 s duration were considered. At study end,
in the intervention group, 52 patients were analyzed, and 51 in
the placebo group. Mean treatment duration was 17 days, and AF
developed in 43% of the placebo group, and 56% of the interven-
tion group (n.s.). Hospital stay and other parameters were also
not signiﬁcantly different. The authors concluded that “omega-3
PUFA do not reduce the risk of AF after coronary artery bypass
graft surgery” (Saravanan et al., 2010).
A similar, randomized double-blind single-center trial was con-
ducted in Iceland, for which 170 patients were recruited (Heidars-
dottir et al., 2010). Patients were started 5–7 days preoperatively
either on two soft capsules daily, totaling either 1240mgof EPAand
1000mg DHA as ethyl-esters (84 patients), or olive oil as a placebo
(86 patients). Sample size was calculated based on an expected
incidence of postoperative AF of 40% in the placebo group, a
reduction to 20% by the intervention, and the usual assump-
tions. At study end, 83 patients were evaluated in the intervention
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group, and 85 in the placebo group. Onset of AF of a duration
of >5min was assessed by continuous electrographic monitor-
ing. Treatment duration was 2–28 days, and postoperative AF was
observed in 54.2% in the intervention group and in 54.1% of
the placebo group (n.s.), although EPA and DHA were signiﬁ-
cantly higher in plasma phospholipids in the intervention group
than in the control group (p< 0.01). Other outcomes were not
signiﬁcantly different, including safety parameters. The authors
concluded that “There is no evidence for a beneﬁcial effect of
treatment with n−3 PUFA on the occurrence of postoperative AF
in patients undergoing open heart surgery” (Heidarsdottir et al.,
2010). In a substudy in the 140 patients undergoing coronary
bypass grafting, it was found that EPA and DHA might prevent
AF in patients with low plasma phospholipid baseline levels of
EPA and DHA, but might be harmful in those with high levels
(Skuladottir et al., 2011). These ﬁndings, however, were not very
robust.
In an observatory study in 530 Italian patients undergoing car-
diac surgery,preoperative intake of 860mgEPA+DHAethyl-ester
for a median of 5 days by 16% of the population was associated
with a decreased incidence of early, but not late AF after cardiac
surgery (Mariscalco et al., 2010).
InAustralia, for a single-center randomized controlled, double-
blind study, 200 patients were randomized after a coronary bypass
or cardiac valve operation (Farquharson et al., 2011). A ﬁsh oil,
providing a daily dose of 4.5 g EPA+DHA was compared to
another oil, largely containing oleic acid, in the form of 15ml
liquid, which was to be taken from 3weeks pre-operatively on.
The primary outcome was occurrence of sustained AF/atrial ﬂut-
ter (duration ≥10min or requiring intervention) during the ﬁrst
6 postoperative days. Sample size was calculated based on an
expected incidence of postoperative AF in 42% of patients, a 53%
relative risk reduction and the usual assumptions. An intention-
to-treat analysis was performed in the 194 participants operated
upon. Onset of AF was assessed based on continuous electrocar-
diographic monitoring. In the intervention group, EPA and DHA
increased in red cells from 5.91± 1.10 to 8.80± 1.73% (p< 0.05),
but remained stable in the control group. AF occurred in 47 of
97 (48%) in the control group and 36 of 97 (37%) in the ﬁsh
oil group (p = 0.11). Time to AF was non-signiﬁcantly longer
(p = 0.06), and stay in the ICU signiﬁcantly shorter (p = 0.005)
in the intervention group, adverse events were evenly distributed.
The authors concluded that “dietary ﬁsh oil did not result in a
signiﬁcant decrease in the incidence of postsurgical AF,” but noted
the signiﬁcant decrease in time spent in the intensive care unit
(Farquharson et al., 2011).
A systematic review on trials on prevention of new-onset post-
operative AF that did not include the Australian trial, noted non-
signiﬁcant reductions in the occurrence of postoperative AF of
22% (OR, 95% CI 0.48–1.27), and called for larger trials (Liu et al.,
2011). One larger trial is currently ongoing (Mozaffarian et al.,
2011b). Whether new-onset postoperative AF can be considered
a model for new-onset of AF without a prior cardiac operation
remains a matter of debate. However, as demonstrated by the tri-
als discussed above, new-onset postoperative AF is a common and
unresolved problem after cardiac surgery, and any formof effective
low-risk prevention would be welcome.
New-onset of AF
In an observatory study, based on an Italian population of
2,239,205 subjects, using hospital discharge records, prescription
databases, and the civil registry, patients discharged after an acute
myocardial infarction free of AF, were monitored for 360 days for
death from any cause and for new-onset AF (Macchia et al., 2008).
Those prescribed EPA+DHA had a relative risk for hospitaliza-
tion for AF of 0.19 (hazard ratio, 95% CI 0.07–0.51], and for
all-cause mortality of 0.15 (hazard ratio of 95% CI 0.05–0.46).
Another observatory study in 2174 Finnish subjects, followed for
17.7 years, 240 developed newAF (Virtanen et al., 2009). The quar-
tile with the highest serum DHA had a relative risk for new AF of
0.64 (hazard ratio, 95% CI 0.42–0.92). A publication from the
Women’s Health Initiative saw no relation between ﬁsh intake and
new-onset of AF in 44,720 participants, subjected to electrocar-
diograms after 3 and 6 years (Berry et al., 2010). In contrast, in
an Italian study, the red cells of 40 patients with AF/atrial ﬂutter
contained a higher percentage of EPA and DHA than those of 53
controls (Viviani Anselmi et al., 2010). In keeping, a report from
the Framingham study saw an increased risk for incident AF with
>4 servings of dark ﬁsh (Shen et al., 2011). Clearly, to deﬁne the
role of EPA and DHA in prevention of new-onset of AF, a large
scale clinical trial is required. The author is part of a world-wide
effort to make such a trial possible.
Prevention of recurrent AF
In an observational study on 1500 patients undergoing catheter
ablation, 285 were treated with omega-3 fatty acids (Patel et al.,
2010). Of those 129 were matched to 129 controls. Of the patients
treated with omega-3 fatty acids, 35 (27.1%) had early recurrence
vs. 57 (44.1%) in the control group (p< 0.0001). Less procedural
failures were observed in the treated group (p< 0.003; Patel et al.,
2010).
A multi-center randomized controlled double-blind 24-week
trial was conducted in 663 US outpatient participants with con-
ﬁrmed symptomatic paroxysmal (n = 542) or persistent (n = 121)
AF (Kowey et al., 2010). Participants received either four 1 g cap-
sules per day of an 85% ﬁsh oil concentrate in the form of an
ethyl-ester (332 patients), or identical capsules containing olive
oil as a placebo (331 patients). The primary end point was a ﬁrst
symptomatic recurrence of AF in participants with paroxysmal
AF. Study size was based on a 32% risk reduction, and the trial
was to be stopped at 295 primary endpoints (Pratt et al., 2009).
Five hundred eighty-four participants completed the study. Data
were analyzed according to modiﬁed intention-to-treat. Although
EPA and DHA increased in plasma, no differences were noted in
the primary endpoint: in participants with paroxysmal AF (haz-
ard ratio, 1.15; 95% CI 0.90–1.46; p = 0.26), or in participants
with persistent AF (HR, 1.64; 95% CI 0.92–2.92; p = 0.09), or both
combined (HR,1.22; 95%CI 0.98–1.52; p = 0.08). Secondary end-
points also did not differ. Heart rate during the recurrent AF was
lower in the group with EPA+DHA by 6.88 bpm than in the con-
trol group. Untoward effects were evenly distributed. The authors
concluded that “Among participants with paroxysmal AF, 24-week
treatment with prescription omega-3 compared with placebo did
not reduce recurrent AF over 6months” (Pratt et al., 2009; Kowey
et al., 2010).
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Whether three 1 g capsules of an 85% EPA+DHA ethyl-
ester would prevent recurrence of AF after electric cardiover-
sion was tested in a multi-center randomized controlled double-
blind 6month trial in Italy vs. an olive oil placebo (Bian-
coni et al., 2011). Patients were included, if AF had persisted
>1month. The primary endpoint was the percentage of recur-
rence, and study sized was based on a recurrence of 50% in
control patients, and 35% in intervention patients, and the
usual assumptions. Into the intervention group, 111 patients
were recruited, and 103 into the placebo group. Included into
the analysis were 104 patients (intervention) and 100 (placebo).
EPA and DHA increased signiﬁcantly in the intervention group,
but remained stable in the control group. Sinus rhythm was
restored, either spontaneously or after electric cardioversion, in
187 patients (91.7%); 95 patients (91.4%) on EPA+DHA, and
92 patients (92.0%) on placebo (p = n.s.). AF relapsed in 56
(58.9%) on EPA+DHA and in 47 (51.1%) of the placebo patients
(p = n.s.). The mean time to AF recurrence was 83+ 8 days in
the EPA+DHA group and 106+ 9 days in the placebo group
(p = n.s.). Adverse events were evenly distributed. The authors
concluded that their “results do not support the hypothesis that
in patients undergoing electric cardioversion of chronic persis-
tent AF, supplementation with PUFAs in addition to the usual
anti-arrhythmic treatment reduces recurrent AF” (Bianconi et al.,
2011).
Very recently, a similar randomized controlled double-blind
single-center trial was published from Italy (Nodari et al., 2011).
Two 1 g capsules contained either a 85% EPA+DHA ethyl-ester
or an olive oil placebo. Patients with persistent AF were included,
if they had at least one relapse after a previous cardioversion,
had an atrial size of >60mm in a echocardiogram, but all were
treatedwith amiodarone and an inhibitor of the renin–angiotensin
system. Patients were pre-treated for 4weeks before electric car-
dioversion. The primary endpoint was the probability of AF after
1 year. Study size was estimated based on a relapse rate of 50%,
a 20% reduction of that rate by the intervention and the usual
assumptions. Into the intervention group, 102, into the placebo
group 103 patients were recruited, and in both groups 94 patients
completed the study, but the analysis was intention-to-treat. The
probability of maintenance of sinus rhythm was higher in the
intervention group than in the placebo group (HR 0.62, 95%
CI 0.52–0.72, p< 0.0001). Adverse effects were minor in both
groups. The authors concluded that EPA+DHA may exert ben-
eﬁcial effects in the prevention of AF recurrence,” and state that
“Further studies are needed to conﬁrm and expand our ﬁndings”
(Nodari et al., 2011).
During writing of this review, results of an open, uncon-
trolled single-center intervention were reported (Watanabe et al.,
2011). For 6months, patients with paroxysmal AF were on either
propafenone or ﬂecainide, and for the subsequent 6months 1.8 g
EPA-ethyl-ester/day was added. While 51 patients commenced
the study, one patient developed a skin rash after 2 days of EPA,
and thus 50 patients were evaluated. An estimation of study size
was not reported. AF was assessed by self-recorded electrocardio-
grams. The primary endpoint, AF burden, deﬁned as the number
of days of AF per month, was not different before and after the
intervention with EPA (Watanabe et al., 2011).
The systematic review alreadymentioned additionally included
other trials on recurrent AF published in abstract form, and found
an overall reduction of recurrent AF of 17% (OR, 95%CO 0.48–
1.45; Liu et al., 2011). Taken together, epidemiologic ﬁndings and
the results of the intervention trials reported thus farmake preven-
tion of recurrent AF after electric cardioversion with EPA +DHA
a promising target for further research. A number of such studies
are currently ongoing (c.f. clinicaltrials.gov).
VENTRICULAR ARRHYTHMIAS
Intermediate parameters
In an epidemiologic study in 260 patients with acute myocardial
infarction, intake of omega-3 fatty acids was found to correlate
inversely with premature ventricular beats (Smith et al., 2009). In
an epidemiologic study in 707 Alaskan natives, a signiﬁcant neg-
ative association between heart rate and the omega-3 Index was
seen (Ebbesson et al., 2010). In two small studies,VT’s were found
to be less inducible in the electrophysiology laboratory after a 6-
week intake of 900mg EPA+DHA/day, or acute infusion of 3.9 g
EPA+DHA (Metcalf et al., 2008; Madsen et al., 2010).
Studies in carriers of an implanted cardioverter-deﬁbrillator
A meta-analysis on the three trials evaluating the effects of EPA
and DHA in a total of 1148 carriers of an implanted cardioverter-
deﬁbrillator (ICD) concluded that “These ﬁndings do not support
a protective effect of omega-3 PUFAs from ﬁsh oil on cardiac
arrhythmia in all patients with an ICD,”and felt the same to be true
for all subgroups (Brouwer et al., 2010). A retrospective analysis
of the 566 participants carrying an ICD in the GISSI-Heart failure
trial found a similar result, but concluded that “The results of this
study, though not statistically signiﬁcant, support prior evidences
of an anti-arrhythmic effect of n−3 PUFA in patients with ICD”
(Finzi et al., 2011). Of note, a relatively small study in 102 German
carriers of an ICD found that the higher the content of red blood
cells in EPA+DHA, the higher the likelihood of an action of the
ICD (Wilhelm et al., 2008). Interestingly, the authors noted that
“These arrhythmias (VT’s) were more often monomorphic and
had a longer average cycle length, suggesting reentrant mecha-
nism. These arrhythmias are not necessarily life-threatening.” In a
randomized controlled trial in 44 carriers of an ICD, among other
parameters, microvolt T-wave analysis improved, heart rate vari-
ability increased and the heart rate of non-sustainedVT decreased
(Nodari et al., 2009) Taken together, the results of the ICD-studies
support the need to differentiate the cause of the action of the ICD
(VT vs. VF), and the action of the ICD (anti-tachycardia pacing
vs. shock) in such studies, as discussed earlier (von Schacky, 2008)
to get a clearer picture of the effects of EPA and DHA in carriers
of an ICD.
Sudden cardiac death
In an epidemiologic study, long-term ﬁsh consumption was asso-
ciated with a lower risk for SCD (Streppel et al., 2008). This is in
keeping with the observation that a low omega-3 index increased
the risk of ventricular ﬁbrillation during the acute ischemic phase
of a myocardial infarction (Aarsetoey et al., 2008), and the obser-
vation that a low omega-3 index was found to be associated with
SCD (Aarsetoey et al., 2011).Of note, a 1% increase of the omega-3
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index was associated with a 58% (95% CI 0.25–0.76%) reduction
in risk of VF during the acute phase of a myocardial infarction
(Aarsetoey et al., 2011).
Intervention trials with clinical endpoints
Late 2008, a systematic review of randomized controlled trials of
ﬁsh oil as dietary supplements in humans found a non-signiﬁcant
reduction in SCD (odds ratio, OR0.81, 95% CI 0.52–1.25), but a
signiﬁcant reduction in death from cardiac causes (OR0.80, 95%
CI 0.69–0.92; León et al., 2008). SCD is an elusive endpoint, since
it occurs only in 1.4% of a population after a myocardial infarction
(Marchioli et al., 2002), mandating large study sizes or meta-
analyses of large studies for any intervention to demonstrate an
effect. For that reason, SCD is rarely selected as a primary endpoint
of an intervention study. Combining important clinical events is
the preferred approach.
An example was the Heart Failure trial by the Italian GISSI-
group (Gissi-HF Investigators et al., 2008) Patients with chronic
heart failure of New York Heart Association class II–IV were
recruited, and randomly assigned to 850mg EPA+DHA as ethyl-
ester daily (n = 3494) or to a matching placebo (n = 3481). The
trial had two co-primary endpoints: time to death and time to
death or admission to hospital for cardiovascular reasons. Study
size was estimated based on a 15% relative reduction of the
expected absolute mortality rate of 25% during 3 years and 90%
power and a two-sided signiﬁcance of 0.045. Analysis was by
intention-to-treat. EPA+DHA were as safe and as tolerable as
placebo.After 3.9 years, time to deathwas reduced by 9% [adjusted
hazard ratio (HR) 0.91, 95.5% CI 0.833–0.998, p = 0.041], while
time to death or admission to hospital for cardiovascular rea-
sons was reduced by 8% (adjusted HR 0.92, 99% CI 0.849.0.999,
p = 0.009). Adjustments were predeﬁned and due to baseline
inequalities. In the intervention group, 274 participants (7.8%)
died a presumably arrhythmic death, in contrast to 304 partic-
ipants (8.7%) in the placebo group (adjusted HR 0·88, 95% CI
0·75–1·04, p = 0.141). SCD occurred in 307 (9%) patients allo-
cated to n−3 PUFA and 325 (9%) in the placebo group (adjusted
HR 0.93, 95% CI 0.79–1.08, p = 0.333). The authors concluded
that “n−3 PUFA can provide a small beneﬁcial advantage in terms
of mortality and admission to hospital for cardiovascular rea-
sons in patients with heart failure” (Gissi-HF Investigators et al.,
2008).
The Alpha-Omega Trial was a multi-center, double-blind,
placebo-controlled trial in 4837 patients after a myocardial infarc-
tion (Geleijnse et al., 2010; Kromhout et al., 2010). Patients were
randomly assigned to receive four trial margarines: a margarine
supplemented with 400mg of EPA+DHA, a margarine supple-
mented with 2 g of ALA, a margarine supplemented with both, or
a placebo margarine. The primary end point was a combination
of fatal and non-fatal cardiovascular events and cardiac interven-
tions, but SCD was not speciﬁcally followed. Study size estimation
was initially based on a CHD mortality of 4% per year, and the
usual assumptions, but had to be adjusted because of a lower mor-
tality observed. Adjustment led to the combined endpoint just
mentioned. Analysis was by intention-o-treat. Adverse events were
evenly distributed among the four groups. None of the interven-
tions reduced the primary endpoint. The authors concluded that
“Low-dose supplementation with EPA–DHA or ALA did not sig-
niﬁcantly reduce the rate of major cardiovascular events among
patients who had had a myocardial infarction.” Reasons for the
neutral result discussed by the authors were speciﬁcs of the study
population, concomitant pharmacologic treatment, and the low-
dose given (Kromhout et al., 2010). Elsewhere, a relatively high
background intake of EPA+DHA was discussed (Mozaffarian
and Wu, 2011). More recently, the authors of the Alpha-Omega
Trial reported a protective effect against ventricular arrhythmia-
related events in the subgroup of post-MI patients with diabetes
(Kromhout et al., 2011).
At least in the ﬁeld of omega-3 fatty acids, the only trial
ambitiously using SCD as a primary endpoint was “OMEGA,” a
randomized, placebo-controlled, double-blind, multi-center trial
comparing 1 g/day EPA+DHA as an ethyl-ester to an olive oil
placebo for 1 year in 3851 German patients shortly after a myocar-
dial infarction (Rauch et al., 2010). Study size was estimated based
on previous registry data with SCD projected to occur in 1.9% in
the group treated with omega-3 acid ethyl-esters 90 and 3.5% in
the placebo group, and alpha of 2.5% and a power of 80% (Rauch
et al., 2006). Primary analysis was by intention-to-treat, and SCD
occurred in 1.5% of both verum and placebo groups, with other
cardiovascular events also evenly distributed. As is, OMEGA had a
statistical power of 44% to detect the assumed reduction in SCD.
This power obviates any conclusion on the effect of EPA+DHA,
because it remains unclear, whether the intervention tested was
ineffective or the study size was too small. The authors discussed
anunexpected low rate of SCD,cross-contamination by in increase
in ﬁsh consumption, and improvements in drug therapy as reasons
for their results. The authors concluded that “Guideline-adjusted
treatment of acute myocardial infarction results in a low rate of
SCD and other clinical events within 1 year of follow-up, which
could not be shown to be further reduced by the application of
omega-3 fatty acids.” As mentioned, the power of the study does
not permit conclusions with regard to the therapeutic effect of
EPA+DHA. Moreover, in GISSI-P, in the ﬁrst year after a myocar-
dial infarction, the incidence of SCD in the control population
was 1.4%, basically identical to the incidence observed in OMEGA
(Marchioli et al., 2002). In GISSI-P, a highly comparable study
populationparticipated,and treatment conforming current guide-
lines was less frequently applied. Therefore, the conclusion of the
authors of OMEGA is not only scientiﬁcally unsound, but also not
supported by the data presented. Strangely enough, the accom-
panying editorial reiterated the conclusions of OMEGA (Eckel,
2010).
The French SuFOL.OM3 trial was a randomized double-blind
multi-center trial, and recruited 2501 participants with a history of
myocardial infarction, unstable angina, or ischemic stroke (Galan
et al., 2010). In a factorial design, 600mg EPA+DHA ethyl-ester
was compared to vitamins, a combination of the two, or placebo.
The primary endpoint was the ﬁrst major cardiovascular event
(e.g., non-fatal and fatal myocardial infarction, stroke, SCD, and
others). Study size was based on an annual event rate of 0.087,
a 10% relative reduction by one intervention (19% by two), a
power of 90%, and a two-tailed α of 0.05. In the 4.7-year follow-up
period, an event occurred in 6.3% of participants, with no statisti-
cally signiﬁcant differences between groups. The authors discussed
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low-dose and low statistical power due to a lower than expected
event rate as explanations for the neutral results. The authors
concluded that “the study does not support the routine use of
dietary supplements containing B vitamins or omega-3 fatty acids
for prevention of cardiovascular disease”“after the acute phase of
the initial event.” Again, the power of the study does not permit
conclusions with regard to the therapeutic effect of EPA+DHA,
because of lack of sufﬁcient statistical power.
THE OMEGA-3 INDEX PERSPECTIVE
The omega-3 index was deﬁned as the percentage of EPA+DHA
in red cells, as determined with a highly standardized analytical
method, currently installed in a few laboratories around the world
(Harris and von Schacky, 2004). While mean levels of the omega-
3 index differ from population to population, mean levels had a
statistically normal distribution in all populations studied so far
(von Schacky, 2011). Therefore, in any population, some individ-
uals have relatively high, and some have relatively low levels, while
most are in between. The omega-3 index reﬂects tissue levels of
EPA+DHA, e.g., of the heart (von Schacky, 2011). A low omega-3
index is a strong predictor of future adverse cardiovascular events
(von Schacky, 2011).
Using the omega-3 index to answer the question whether
EPA+DHA are anti- or pro-arrhythmic provides a clearer pic-
ture than the one provided thus far. In Japan, the mean omega-3
index was found to be 9.58% in unselected persons, and the inci-
dence of SCD in the general population 7.8/100,000 person years,
while in Western countries, the mean omega-3 index is frequently
among 5%, and the incidence of SCD in the general population is
150/100,000 person years (von Schacky,2010). In two case–control
studies on SCD in the US, levels of omega-3 fatty acids in red cells
or whole blood were inversely related to risk for SCD, and a 10-
fold difference in risk was reported (von Schacky, 2010). Thus, a
high omega-3 Index, e.g., 8–11%, is associated with a low-risk for
SCD, and risk appears to increase with decreasing values of the
omega-3 index.
Experimental evidence indicates that acute increases in
EPA+DHA concentrations do not have a further anti-arrhythmic
effect in tissues already replete with them (Den Ruijter et al.,
2010). Therefore, it is unlikely that an anti-arrhythmic effect can
be demonstrated in persons or populations with a high omega-3
index, like in Japan. In keeping, in a large randomized interven-
tion study in persons at elevated risk for cardiovascular disease
in Japan (20% of whom had established cardiovascular disease),
1.8 g EPA/day did not reduce SCD (Yokoyama et al., 2007). Of
note, the incidence of SCD in JELIS was 40/100,000, substan-
tially lower than in the general population inWestern countries, as
mentioned above (von Schacky, 2010).However, acute increases in
EPA+DHA,e.g.,by infusionor after a 6-weekdietary intervention
reduced inducibility of ventricular tachycardias, but only in sub-
jects with low levels (Schrepf et al., 2004; Metcalf et al., 2008; Mad-
sen et al., 2010). Although the latter studies were small and short,
current evidence indicates that acute increases of EPA+DHA lev-
els by infusion or a short-term dietary intervention can reduce
the probability of ventricular arrhythmias in those with subopti-
mal levels, but that high tissue levels, reﬂected by a high omega-3
index, are protective.
A lower omega-3 index also makes other adverse outcomes
more likely than a higher omega-3 index:Among the outcomes are
ventricular ﬁbrillation during a myocardial infarction (Aarsetoey
et al., 2011), myocardial infarctions (Block et al., 2008; Park et al.,
2009),mortality after a myocardial infarction (Pottala et al., 2010),
andmanymore reviewed elsewhere (von Schacky, 2011). Support-
ing evidence is provided by plasma measurements of EPA+DHA
(e.g., Mozaffarian et al., 2011a).
The omega-3 index has a lower biological variability than
plasma or whole blood EPA+DHA (Harris and Thomas, 2010).
The level of the omega-3 index is determined by many factors,
among them catabolism of EPA+DHA, age, body mass index,
and intake of EPA+DHA (von Schacky, 2011). Intake, however,
explains<16or 12%of the variability of EPA+DHAin the red cell
membrane (Ebbesson et al., 2010; Sala-Vila et al., 2011). This may
partly explain, why epidemiologic studies focusing on intake of
EPA+DHA provided less clear results than epidemiologic studies
focusing on the omega-3 index (von Schacky, 2010). In the future,
a more widespread use of the omega-3 index in research projects
will provide a clearer picture of associations between EPA +DHA
and cardiovascular events. Already now, however, the omega-3
index fulﬁlls important criteria of the US Preventive Services Task
Force or the American Heart Association for new biomarkers for
cardiovascular risk (Helfand et al., 2009; Hlatky et al., 2009):
1. Ease and reliability of measurement. The analytical methodol-
ogy is standardized in three laboratories around the world, and
conforms to the rules of Clinical Chemistry (e.g., plausibility
checks, proﬁciency testing).
2. Risk predicted independent of conventional risk factors. This
has been demonstrated for an American and a Korean popu-
lation, and was evidenced by a larger area under the curve in
comparison to the Framingham index (Park et al., 2009; Shearer
et al., 2009).
3. Reclassiﬁcation of persons at intermediate risk (Shearer et al.,
2009).
4. Therapeutic consequence. In all populations studied so far, an
increase in intake of EPA+DHA increased the mean omega-
3 index. In meta-analyses, increased intake of EPA+DHA
resulted in decreased occurrence of major cardiovascular events
(e.g., León et al., 2008; Mozaffarian and Wu, 2011). Whether
an omega-3 index based supplementation with EPA+DHA is
superior to the current untargeted use of EPA+DHA remains
to be formally demonstrated, however.
DISCUSSION
Only recently, bioavailability problems of preparations of
EPA+DHA have surfaced. Unfortunately, while ethyl-esters have
been used in most intervention trials, ethyl-esters are the least well
absorbed chemical form of omega-3 fatty acids, and absorption
depends on the fat content of the meal eaten with intake (Dyer-
berg et al., 2010; Neubronner et al., 2011). A lower bioavailability
translates into a lower biological activity (Schuchardt et al., 2011).
Moreover, large differences exist in absorption of EPA +DHA
from individual to individual, even if an identical dose of a chem-
ical form is taken in an identical matrix, in this case 940mg
EPA+DHA from salmon oil (triglyceride) in 200ml of a drink
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(Köhler et al., 2010). Both phenomena impact negatively on the
differentiation between intervention and control groups in terms
of dose of EPA+DHA absorbed.
Moreover, in all intervention trials mentioned, participants
were recruited irrespective of their baseline levels of EPA+DHA.
Participants with a high omega-3 index at baseline are not likely to
develop a cardiovascular event during a trial. In addition, levels of
EPA+DHA achieved in intervention and control groups during
the study will overlap in a substantial portion of study partici-
pants, again negatively impacting on the differentiation between
intervention and control groups in terms of levels of EPA+DHA
achieved. Jointly, the two effects just mentioned produce a ten-
dency toward neutrals results of clinical trials with EPA+DHA. In
the future, recruiting studyparticipantswith a lowbaseline omega-
3 index, and treating to a target omega-3 index (e.g., 8–11%) will
make intervention trials with EPA+DHAmore efﬁcient.Very efﬁ-
cient trials are needed to demonstrate effects of any intervention
on rare endpoints, like SCD or new-onset AF.
Pro-arrhythmic effects have not been seen in any intervention
trial with clinical endpoints, rather arrhythmic events were either
reduced or not signiﬁcantly altered (Marchioli et al., 2002; Gissi-
HF Investigators et al., 2008; León et al., 2008; Galan et al., 2010;
Kromhout et al., 2010; Rauch et al., 2010; Mozaffarian and Wu,
2011). The same phenomenon has been seen in the animal studies
reviewed above. This is in keeping with all but one epidemio-
logic study reporting slowerVT’s the higher the red cell content of
EPA+DHA (Wilhelm et al., 2008). Thus, the data from epidemio-
logic and intervention studies are compatible with the speculation
that EPA+DHA inhibit degeneration of non-fatal VT into fatal
VF. A re-analysis of the original data obtained in the three inter-
vention trials in carriers of an ICD would be a ﬁrst step toward
substantiating this speculation.
Currently, it is unclear, whether the anti-arrhythmic effect of
EPA+DHA is restricted to arrhythmias associated with ischemia
or not. The data reported from the large clinical trials do not
answer this question. The three small studies on inducibility of
VT’s in the electrophysiology laboratory argue in favor of an effect
in the absence of ischemia (Schrepf et al., 2004;Metcalf et al., 2008;
Madsen et al., 2010), as do results from studies using intermediate
or surrogate parameters, such as heart rate, heart rate variability,
or rate of VT’s (discussed above). The observation from Norway
that an 1% increase in the omega-3 index was associated with a
58% reduction in risk of VF during the acute phase of a myocar-
dial infarction (Aarsetoey et al., 2011), supports the notion that
the anti-arrhythmic effect of EPA+DHA becomes speciﬁcally
important in the presence of ischemia. Based on current evidence,
this question cannot be resolved with certainty, however (Raitt,
2009).
CONCLUSION
Taken together, there is no evidence that EPA+DHA are arrhyth-
mic at the atrial level, i.e., that EPA+DHA propagate AF. Rather,
intervention trials so far indicate that there might be a small pre-
ventive effect that needs to be investigated in larger and/or more
efﬁcient trials than conducted so far. This is true for postopera-
tive AF, recurrent AF and new-onset AF. On the ventricular level,
epidemiologic studies indicate a possible anti-arrhythmic effect,
possibly by slowing VT, thus possibly preventing progression to
VF. Results of trials on intermediate endpoints in carriers of an
ICD were inconclusive, possibly because of indiscriminate combi-
nation of endpoints. SCD is a rare event. Unfortunately, the only
intervention trial to study SCD as a primary endpoint was inad-
equately powered, obviating a conclusion on the preventive effect
of EPA+DHA on SCD. Other trials used combinations of end-
points, usually including an arrhythmic endpoint and in no trial,
a pro-arrhythmic effect was found. Due to problems with study
power in another trial, and the possibility of inadequate dosing in
yet another, the anti-arrhythmic effect of EPA+DHAwas recently
demonstrated in only one trial in patients with congestive heart
failure. All trials thus far suffer from a tendency toward a neutral
result, since study participants were recruited irrespective of their
baseline omega-3 index. Rather than indiscriminately recruiting
study participants, use of a low omega-3 index as an inclusion
criterion will make more efﬁcient intervention trials possible, and
will lead to a clearer delineation of mechanisms of action. Use
of the omega-3 index provides a more targeted approach toward
deﬁning the impact of EPA+DHA and/or their derivatives on
cardiac rhythm.
REFERENCES
Aarsetoey, H., Aarsetoey, R., Lindner, T.,
Staines,H.,Harris,W. S., and Nilsen,
D. W. (2011). Low levels of the
omega-3 index are associated with
sudden cardiac arrest and remain
stable in survivors in the subacute
phase. Lipids 46, 151–161.
Aarsetoey, H., Pönitz, V., Nilsen, O.
B., Grundt, H., Harris, W. S., and
Nilsen, D. W. (2008). Low levels
of cellular omega-3 increase the
risk of ventricular ﬁbrillation dur-
ing the acute ischaemic phase of a
myocardial infarction. Resuscitation
78, 258–264.
Abdukeyum, G. G., Owen, A. J., and
McLennan, P. L. (2008). Dietary
(n-3) long-chain polyunsaturated
fatty acids inhibit ischemia and
reperfusion arrhythmias and infarc-
tion in rat heart not enhanced by
ischemic preconditioning. J. Nutr.
138, 1902–1909.
Bacova, B., Radosinska, J., Knezl,
V., Kolenova, L., Weismann,
P., Navarova, J., Barancik, M.,
Mitasikova, M., and Tribulova,
N. (2010). Omega-3 fatty acids
and atorvastatin suppress ven-
tricular ﬁbrillation inducibility
in hypertriglyceridemic rat hearts:
implication of intracellular coupling
protein, connexin-43. J. Physiol.
Pharmacol. 61, 717–723.
Berry, J. D., Prineas, R. J., van Horn, L.,
Passman, R., Larson, J., Goldberger,
J., Snetselaar, L., Tinker, L., Liu,
K., and Lloyd-Jones, D. M. (2010).
Dietary ﬁsh intake and incident
atrial ﬁbrillation (from the Women’s
Health Initiative). Am. J. Cardiol.
105, 844–848.
Bianconi, L., Calò, L., Mennuni, M.,
Santini, L.,Morosetti, P., Azzolini, P.,
Barbato, G., Biscione, F., Romano, P.,
and Santini, M. (2011). n-3 polyun-
saturated fatty acids for the preven-
tion of arrhythmia recurrence after
electrical cardioversion of chronic
persistent atrial ﬁbrillation: a ran-
domized, double-blind, multicentre
study. Europace 13, 174–181.
Billman, G. E., and Harris,W. S. (2011).
Effect of dietary omega-3 fatty acids
on the heart rate and the heart rate
variability responses to myocardial
ischemia or submaximal exercise.
Am. J. Physiol. Heart Circ. Physiol.
300, H2288–H2299.
Billman, G. E., Harris, W. S., Carnes,
C. A., Adamson, P. B., Vanoli, E.,
and Schwartz, P. J. (2012). Dietary
omega-3 fatty acids and susceptibil-
ity to ventricular ﬁbrillation: Lack
of protection and A proarrhythmic
effect. Circ. Arrhythm. Electrophys-
iol. PMID: 22333345. [Epub ahead
of print].
Billman, G. E., Nishijima, Y., Belevych,
A. E., Terentyev, D., Xu, Y., Haizlip,
K. M., Monasky, M. M., Hiranan-
dani, N., Harris, W. S., Gyorke, S.,
Carnes, C. A., and Janssen, P. M.
(2010). Effects of dietary omega-3
fatty acids on ventricular function in
dogs with healed myocardial infarc-
tions: in vivo and in vitro studies.
Am. J. Physiol. Heart Circ. Physiol.
298, H1219–H1228.
Frontiers in Physiology | Cardiac Electrophysiology April 2012 | Volume 3 | Article 88 | 8
von Schacky Omega-3’s and cardiac rhythm
Block, R. C., Harris, W. S., Reid, K. J.,
Sands,S.A., andSpertus, J.A. (2008).
EPA and DHA in blood cell mem-
branes from acute coronary syn-
drome patients and controls. Ather-
osclerosis 197, 821–828.
Brouwer, I. A., Raitt, M. H., Dullemei-
jer, C., Kraemer, D. F., Zock, P. L.,
Morris, C., Katan, M. B., Connor,
W. E., Camm, J. A., Schouten, E. G.,
and McAnulty, J. (2010). Effect of
ﬁsh oil on ventricular tachyarrhyth-
mia in three studies in patients with
implantable cardioverter deﬁbrilla-
tors. Eur. Heart J. 30, 820–826.
Calò, L., Bianconi, L., Colivicchi, F.,
Lamberti, F., Loricchio, M. L., de
Ruvo, E., Meo, A., Pandozi, C.,
Staibano,M., and Santini,M. (2005).
N-3 fatty acids for the prevention
of atrial ﬁbrillation after coronary
artery bypass surgery: a randomized,
controlled trial. J. Am. Coll. Cardiol.
45, 1723–1728.
De Caterina, R. (2011). N-3 fatty acids
in cardiovascular disease. N. Engl. J.
Med. 364, 2439–2450.
Den Ruijter, H. M., Berecki, G., Verk-
erk, A. O., Bakker, D., Baartscheer,
A., Schumacher, C. A., Belterman,
C. N., de Jonge, N., Fiolet, J. W.,
Brouwer, I. A., and Coronel, R.
(2008). Acute administration of ﬁsh
oil inhibits triggered activity in iso-
lated myocytes from rabbits and
patients with heart failure. Circula-
tion 117, 536–544.
Den Ruijter, H. M., Verkerk, A. O.,
and Coronel, R. (2010). Incor-
porated ﬁsh oil fatty acids pre-
vent action potential shortening
induced by circulating ﬁsh oil
fatty acids. Front. Physiol. 1:149.
doi:10.3389/fphys.2010.00149
Dujardin, K. S., Dumotier, B., David,
M., Guizy, M., Valenzuela, C., and
Hondeghem, L. M. (2008). Ultrafast
sodium channel block by dietary ﬁsh
oil prevents dofetilide-induced ven-
tricular arrhythmias in rabbit hearts.
Am. J. Physiol. Heart Circ. Physiol.
295, H1414–H1421.
Dyerberg, J., Madsen, P., Møller, J.
M., Aardestrup, I., and Schmidt,
E. B. (2010). Bioavailability of
marine n-3 fatty acid formulations.
Prostaglandins Leukot. Essent. Fatty
Acids 83, 137–141.
Ebbesson, S. O., Devereux, R. B., Cole,
S., Ebbesson, L. O., Fabsitz, R. R.,
Haack, K., Harris,W. S., Howard,W.
J., Laston, S., Lopez-Alvarenga, J. C.,
MacCluer, J. W., Okin, P. M., Tejero,
M. E., Voruganti, V. S., Wenger, C.
R., Howard, B. V., and Comuzzie, A.
G. (2010). Heart rate is associated
with red blood cell fatty acid con-
centration: theGenetics of Coronary
Artery Disease in Alaska Natives
(GOCADAN) Study. Am. Heart J.
159, 1020–1025.
Eckel, R. H. (2010). The ﬁsh oil
story remains ﬁshy. Circulation 122,
2110–2112.
Falck, J. R., Wallukat, G., Puli, N.,
Goli, M., Arnold, C., Konkel, A.,
Rothe, M., Fischer, R., Müller, D.
N., and Schunck, W. H. (2011).
17(R),18(S)-epoxyeicosatetraenoic
acid, a potent eicosapentaenoic
acid (EPA) derived regulator
of cardiomyocyte contraction:
structure-activity relationships and
stable analogues. J. Med. Chem. 54,
4109–4118.
Farquharson, A. L., Metcalf, R. G.,
Sanders, P., Stuklis, R., Edwards, J.
R., Gibson, R. A., Cleland, L. G., Sul-
livan, T. R., James, M. J., and Young,
G. D. (2011). Effect of dietary ﬁsh
oil on atrial ﬁbrillation after car-
diac surgery. Am. J. Cardiol. 108,
851–856.
Finzi, A. A., Latini, R., Barlera, S., Rossi,
M. G., Ruggeri, A., Mezzani, A.,
Favero, C., Franzosi,M. G., Serra, D.,
Lucci, D., Bianchini, F., Bernasconi,
R., Maggioni, A. P., Nicolosi, G.,
Porcu, M., Tognoni, G., Tavazzi, L.,
and Marchioli, R. (2011). Effects of
n-3 polyunsaturated fatty acids on
malignant ventricular arrhythmias
in patients with chronic heart failure
and implantable cardioverter-
deﬁbrillators: a substudy of the
Gruppo Italiano per lo Studio della
Sopravvivenza nell’Insufﬁcienza
Cardiaca (GISSI-HF) trial. Am.
Heart J. 161, 338–343.
Galan, P., Kesse-Guyot, E., Czernichow,
S., Briancon, S., Blacher, J.,Hercberg,
S., and SU.FOL.OM3 Collaborative
Group. (2010). Effects of B vitamins
and omega 3 fatty acids on car-
diovascular diseases: a randomised
placebo controlled trial. BMJ 341,
c6273.
Geleijnse, J. M., Giltay, E. J., Schouten,
E. G., de Goede, J., Oude Griep, L.
M., Teitsma-Jansen, A. M., Katan,
M. B., and Kromhout, D. (2010).
Alpha Omega Trial Group. Effect
of low doses of n-3 fatty acids
on cardiovascular diseases in 4,837
post-myocardial infarction patients:
design andbaseline characteristics of
the Alpha Omega Trial. Am. Heart J.
159, 539–546.
Gissi-HF Investigators, Tavazzi, L.,
Maggioni, A. P., Marchioli, R.,
Barlera, S., Franzosi, M. G., Latini,
R., Lucci, D., Nicolosi, G. L., Porcu,
M., and Tognoni, G. (2008). Effect
of n-3 polyunsaturated fatty acids in
patients with chronic heart failure
(the GISSI-HF trial): a randomised,
double-blind, placebo-controlled
trial. Lancet 372, 1223–1230.
Gronroos, N. N., and Alonso, A. (2010).
Diet and risk of atrial ﬁbrillation –
epidemiologic and clinical evidence.
Circ. J. 74, 2029–2038.
Harris, W. S., and Thomas, R. M.
(2010). Biological variability of
blood omega-3 biomarkers. Clin.
Biochem. 43, 338–340.
Harris, W. S., and von Schacky, C.
(2004). The omega-3 index: a new
risk factor for death from coro-
nary heart disease? Prev. Med. 39,
212–220.
Heidarsdottir, R., Arnar, D. O., Sku-
ladottir, G. V., Torfason, B., Edvards-
son, V., Gottskalksson, G., Palsson,
R., and Indridason, O. S. (2010).
Does treatment with n-3 polyun-
saturated fatty acids prevent atrial
ﬁbrillation after open heart surgery?
Europace 12, 356–363.
Heidt, M. C., Vician, M., Stracke, S. K.,
Stadlbauer, T., Grebe, M. T., Boen-
ing, A., Vogt, P. R., and Erdogan, A.
(2009). Beneﬁcial effects of intra-
venously administered N-3 fatty
acids for the prevention of atrial ﬁb-
rillation after coronary artery bypass
surgery: a prospective randomized
study. Thorac. Cardiovasc. Surg. 57,
276–280.
Helfand, M., Buckley, D. I., Freeman,
M., Fu, R., Rogers, K., Fleming, C.,
and Humphrey, L. L. (2009). Emerg-
ing risk factors for coronary heart
disease: a summary of systematic
reviews conducted for the U.S. Pre-
ventive Services Task Force. Ann.
Intern. Med. 151, 496–507.
Hlatky, M. A., Greenland, P., Arnett,
D. K., Ballantyne, C. M., Criqui, M.
H., Elkind, M. S., Go, A. S., Har-
rell, F. E. Jr., Hong, Y., Howard, B.
V., Howard,V. J., Hsue, P. Y., Kramer,
C. M., McConnell, J. P., Normand,
S. L., O’Donnell, C. J., Smith, S. C.
Jr., and Wilson, P. W. (2009). Ameri-
can Heart Association expert panel
on subclinical atherosclerotic dis-
eases and emerging risk factors and
the Stroke Council. Circulation 119,
2408–2416.
Huggins, C. E., Curl, C. L., Patel, R.,
McLennan, P. L., Theiss, M. L.,
Pedrazzini, T., Pepe, S., and Del-
bridge, L. M. (2009). Dietary ﬁsh
oil is antihypertrophic but does
not enhance postischemic myocar-
dial function in female mice. Am.
J. Physiol. Heart Circ. Physiol. 296,
H957–H966.
Kitamura, K., Shibata, R., Tsuji, Y., Shi-
mano, M., Inden, Y., and Muro-
hara, T. (2011). Eicosapentaenoic
acid prevents atrial ﬁbrillation asso-
ciated with heart failure in a rabbit
model. Am. J. Physiol. Heart Circ.
Physiol. 300, H1814–H1821.
Köhler, A., Bittner, D., Löw, A., and
von Schacky, C. (2010). Effects of a
convenience drink fortiﬁed with n-
3 fatty acids on the n-3 index. Br. J.
Nutr. 104, 729–736.
Kowey, P. R., Reiffel, J. A., Ellenbogen,
K. A., Naccarelli, G. V., and Pratt,
C. M. (2010). Efﬁcacy and safety of
prescription omega-3 fatty acids for
the prevention of recurrent sympto-
matic atrial ﬁbrillation: a random-
ized controlled trial. J. Am. Med.
Assoc. 304, 2363–2372.
Kromhout, D., Geleijnse, J. M., de
Goede, J., Oude Griep, L. M., Mul-
der, B. J., de Boer, M. J., Deck-
ers, J. W., Boersma, E., Zock, P.
L., and Giltay, E. J. (2011). n-3
fatty acids, ventricular arrhythmia-
related events, and fatal myocardial
infarction in postmyocardial infarc-
tion patients with diabetes. Diabetes
Care 34, 2515–2520.
Kromhout, D., Giltay, E. J., Geleijnse, J.
M., and Alpha Omega Trial Group.
(2010). N-3 fatty acids and car-
diovascular events after myocardial
infarction. N. Engl. J. Med. 363,
2015–2026.
Kumar, S., Sutherland, F., The, A. W.,
Heck, P. M., Lee, G., Garg, M. L.,
and Sparks, P. B. (2011a). Effects
of chronic omega-3 polyunsatu-
rated fatty acid supplementation on
human pulmonary vein and left
atrial electrophysiology in paroxys-
mal atrial ﬁbrillation. Am. J. Cardiol.
108, 531–535.
Kumar, S., Sutherland, F., Rosso,R., The,
A. W., Lee, G., Heck, P. M., Feld-
man, A., Medi, C., Watt, S., Garg,
M. L., and Sparks, P. B. (2011b).
Effects of chronic omega-3 polyun-
saturated fatty acid supplementation
on human atrial electrophysiology.
Heart Rhythm 8, 562–568.
Kumar, S., Sutherland, F., Wheeler, M.,
Heck,P.M.,Lee,G.,The,A.W.,Garg,
M. L.,Morgan, J. G., and Sparks, P. B.
(2011c). Effects of chronic omega-3
polyunsaturated fatty acid supple-
mentation on human atrialmechan-
ical function after reversion of atrial
arrhythmias to sinus rhythm: rever-
sal of tachycardia-mediated atrial
cardiomyopathy with ﬁsh oils. Heart
Rhythm 8, 643–649.
León, H., Shibata, M. C., Sivakumaran,
S., Dorgan, M., Chatterley, T., and
Tsuyuki, R. T. (2008). Effect of ﬁsh
oil on arrhythmias and mortality:
systematic review. BMJ 337, a2931.
Liu, T., Korantzopoulos, P., Shehata, M.,
Li, G.,Wang, X., and Kaul, S. (2011).
Prevention of atrial ﬁbrillation with
omega-3 fatty acids: a meta-analysis
www.frontiersin.org April 2012 | Volume 3 | Article 88 | 9
von Schacky Omega-3’s and cardiac rhythm
of randomised clinical trials. Heart
97, 1034–1040.
Macchia, A., Monte, S., Pellegrini, F.,
Romero, M., Ferrante, D., Doval,
H., D’Ettorre, A., Maggioni, A. P.,
and Tognoni, G. (2008). Omega-3
fatty acid supplementation reduces
one-year risk of atrial ﬁbrillation in
patients hospitalized with myocar-
dial infarction. Eur. J. Clin. Pharma-
col. 64, 627–634.
Madsen, T., Christensen, J. H.,
Thøgersen, A. M., Schmidt, E.
B., and Toft, E. (2010). Intravenous
infusion of n-3 polyunsaturated
fatty acids and inducibility of
ventricular tachycardia in patients
with implantable cardioverter
deﬁbrillator. Europace 12, 941–946.
Marchioli, R., Barzi, F., Bomba, E., Chi-
effo, C., Di Gregorio, D., Di Mascio,
R., Franzosi, M. G., Geraci, E., Lev-
antesi, G., Maggioni, A. P., Mantini,
L., Marﬁsi, R. M., Mastrogiuseppe,
G., Mininni, N., Nicolosi, G. L.,
Santini, M., Schweiger, C., Tavazzi,
L., Tognoni, G., Tucci, C., Vala-
gussa, F., and GISSI-Prevenzione
Investigators. (2002). Early protec-
tion against sudden death by n-
3 polyunsaturated fatty acids after
myocardial infarction. Time-course
analysis of the results of the




Mariscalco, G., Sarzi Braga, S., Banach,
M., Borsani, P., Bruno, V. D.,
Napoleone, M., Vitale, C., Piffaretti,
G., Pedretti, R. F., and Sala, A.
(2010). Preoperative n-3 polyunsat-
urated fatty acids are associated with
a decrease in the incidence of early
atrial ﬁbrillation following cardiac
surgery. Angiology 61, 643–650.
Mayyas, F., Sakurai, S., Ram, R., Renni-
son, J. H., Hwang, E. S., Castel, L.,
Lovano, B., Brennan, M. L., Bibus,
D., Lands, B., Barnard, J., Chung,
M. K., and Van Wagoner, D. R.
(2011). Dietary ω3 fatty acids mod-
ulate the substrate for post-operative
atrial ﬁbrillation in a canine cardiac
surgery model. Cardiovasc. Res. 89,
852–861.
Metcalf, R. G., Sanders, P., James, M.
J., Cleland, L. G., and Young, G.
D. (2008). Effect of dietary n-3
polyunsaturated fatty acids on the
inducibility of ventricular tachycar-
dia in patients with ischemic car-
diomyopathy. Am. J. Cardiol. 101,
758–761.
Mitasíková, M., Smidová, S., Mac-
saliová, A., Knezl, V., Dlugosová, K.,
Okruhlicová, L., Weismann, P., and
Tribulová, N. (2008). Aged male
and female spontaneously hyperten-
sive rats beneﬁt from n-3 polyun-
saturated fatty acids supplemen-
tation. Physiol. Res. 57(Suppl. 2),
S39–S48.
Mozaffarian, D., Lemaitre, E. N., King,
I. B., Song, X., Spiegelman,D., Sacks,
F. M., Rimm, E. B., and Siscovick,
D. S. (2011a). Circulating long-chain
ω-3 fatty acids and incidence of con-
gestive heart failure in older adults:
the cardiovascular health study. a
cohort study. Ann. Intern. Med. 155,
160–179.
Mozaffarian, D., Marchioli, R., Gard-
ner, T., Ferrazzi, P.,O’Gara, P., Latini,
R., Libby, P., Lombardi, F., Macchia,
A., Page, R., Santini, M., Tavazzi, L.,
and Tognoni, G. (2011b). The ω-3
fatty acids for prevention of post-
operative atrial ﬁbrillation trial –
rationale and design. Am. Heart J.
162, 56–63.
Mozaffarian, D., and Wu, J. H. (2011).
Omega-3 fatty acids and cardiovas-
cular disease: effects on risk fac-
tors, molecular pathways, and clin-
ical events. J. Am. Coll. Cardiol. 58,
2047–2067.
Neubronner, J., Schuchardt, J. P.,Kressel,
G., Merkel, M., von Schacky, C., and
Hahn, A. (2011). Enhanced increase
of omega-3 index in response to
long-term n-3 fatty acid supplemen-
tation from triacylglycerides versus
ethyl esters. Eur. J. Clin. Nutr. 65,
247–254.
Nodari, S., Metra, M., Milesi, G.,
Manerba, A., Cesana, B. M., Gheo-
rghiade, M., and Dei Cas, L. (2009).
The role of n-3 PUFAs in preventing
the arrhythmic risk in patients with
idiopathic dilated cardiomyopathy.
Cardiovasc. Drugs Ther. 23, 5–15.
Nodari, S., Triggiani, M., Campia, U.,
Manerba, A., Milesi, G., Cesana, B.
M., Gheorghiade, M., and Dei Cas,
L. (2011). n-3 polyunsaturated fatty
acids in the prevention of atrial
ﬁbrillation recurrences after elec-
trical cardioversion: a prospective,
randomized study. Circulation 124,
1100–1106.
Park, Y., Lim, J., Lee, J., and Kim, S.
G. (2009). Erythrocyte fatty acid
proﬁles can predict acute non-fatal
myocardial infarction. Br. J. Nutr.
102, 1355–1356.
Patel, D., Shaheen, M., Venkatraman, P.,
Armaganijan, L., Sanchez, J. E., Hor-
ton, R. P., Di Biase, L., Mohanty, P.,
Canby, R., Bailey, S. M., Burkhardt, J.
D., Gallinghouse, G. J., Zagrodzky, J.
D., Kozeluhova, M., and Natale, A.
(2010). Omega-3 polyunsaturated
fatty acid supplementation reduced
atrial ﬁbrillation recurrence after
pulmonary vein antrum isolation.
Indian Pacing Electrophysiol. J. 9,
292–298.
Peltier, S., Louchami, K., Zhang, Y., Por-
tois, L., Hacquebard, M., Malaisse,
W. J., and Carpentier, Y. A. (2009).
Alteration of lipid fatty acid pro-
ﬁle and cationic ﬂuxes in ventric-
ular cardiomyocytes from omega3-
depleted rats. Int. J. Mol. Med. 24,
343–352.
Pottala, J. V., Garg, S., Cohen, B. E.,
Whooley, M. A., and Harris, W. S.
(2010). Blood Eicosapentaenoic and
docosahexaenoic acids predict all-
cause mortality in patients with sta-
ble coronary heart disease: the heart
and soul study. Circ. Cardiovasc.
Qual. Outcomes 3, 406–412.
Pratt, C. M., Reiffel, J. A., Ellenbogen,
K. A., Naccarelli, G. V., and Kowey,
P. R. (2009). Efﬁcacy and safety
of prescription omega-3-acid ethyl
esters for the prevention of recur-
rent symptomatic atrial ﬁbrillation:
a prospective study.Am.Heart J. 158,
163–169.
Raitt, M. H. (2009). Are n-3 polyunsat-
urated fatty acids antiarrhythmic in
the absence of ischemia? Editorial to:
“the role of n-3 PUFAs in preventing
the arrhythmic risk in patients with
idiopathic dilated cardiomyopathy”
by S. Nodari et al. Cardiovasc. Drugs
Ther. 23, 1–3.
Ramadeen, A., Connelly, K. A., Leong-
Poi, H., Hu, X., Fujii, H., Van
Krieken, R., Van Laurent, G., Holub,
B. J., Bazinet, R. P., and Dorian,
P. (2012). N-3 polyunsaturated
fatty acid supplementation does not
reduce vulnerability to atrial ﬁb-
rillation in remodeling atria. Heart
Rhythm. PMID: 22342864. [Epub
ahead of print].
Ramadeen, A., Laurent, G., dos San-
tos, C. C., Hu, X., Connelly, K.
A., Holub, B. J., Mangat, I., and
Dorian, P. (2010). n-3 Polyunsatu-
rated fatty acids alter expression of
ﬁbrotic and hypertrophic genes in a
dog model of atrial cardiomyopathy.
Heart Rhythm 7, 520–528.
Rauch, B., Schiele, R., Schneider, S.,
Diller, F., Victor, N., Gohlke, H.,
Gottwik, M., Steinbeck, G., Del
Castillo, U., Sack, R., Worth, H.,
Katus,H., Spitzer,W., Sabin,G., Sen-
ges, J., and OMEGA Study Group.
(2010). OMEGA, a randomized,
placebo-controlled trial to test the
effect of highly puriﬁed omega-
3 fatty acids on top of mod-
ern guideline-adjusted therapy after
myocardial infarction. Circulation
122, 2152–2159.
Rauch, B., Schiele, R., Schneider, S.,
Gohlke, H., Diller, F., Gottwik, M.,
Steinbeck, G., Heer, T., Katus, H.,
Zimmer, R., Erdogan, A., Pfaffer-
ott, C., Senges, J., and Omega-
Study Group. (2006). Highly puri-
ﬁed omega-3 fatty acids for sec-
ondary preventionof sudden cardiac
death after myocardial infarction-
aims and methods of the OMEGA-
study. Cardiovasc. Drugs Ther. 20,
365–375.
Richardson, E. S., Iaizzo, P. A., and Xiao,
Y. F. (2011). Electrophysiological
mechanisms of the anti-arrhythmic
effects of omega-3 fatty acids. J.
Cardiovasc. Transl. Res. 4, 42–52.
Sala-Vila, A., Harris, W. S., Cofán,
M., Pérez-Heras, A. M., Pintó, X.,
Lamuela-Raventós, R. M., Covas, M.
I., Estruch, R., and Ros, E. (2011).
Determinants of the omega-3 index
in a Mediterranean population at
increased risk for CHD. Br. J. Nutr.
106, 425–431.
Saravanan, P., Bridgewater, B., West, A.
L., O’Neill, S. C., Calder, P. C., and
Davidson, N. C. (2010). Omega-
3 fatty acid supplementation does
not reduce risk of atrial ﬁbrilla-
tion after coronary artery bypass
surgery: a randomized, double-
blind, placebo-controlled clinical
trial. Circ. Arrhythm. Electrophysiol.
3, 46–53.
Savelieva, I., Kakouros, N., Kourliouros,
A., and Camm, A. J. (2011).
Upstream therapies for manage-
ment of atrial ﬁbrillation: review of
clinical evidence and implications
for European Society of Cardiol-
ogy guidelines. Part II: secondary
prevention. Europace 13, 610–625.
Schrepf, R., Limmert, T., Weber, P.
C., Theisen, K., and Sellmayer, A.
(2004). Immediate effects of n-3
fatty acid infusion on the induction
of sustained ventricular tachycardia.
Lancet 363, 1441–1442.
Schuchardt, J. P., Neubronner, J., Kres-
sel, G., Merkel, M., von Schacky,
C., and Hahn, A. (2011). Mod-
erate doses of EPA and DHA
from re-esteriﬁed triacylglycerols
but not from ethyl-esters lower
fasting serum triacylglycerols in
statin-treated dyslipidemic subjects:
results from a six month random-
ized controlled trial. Prostaglandins
Leukot. Essent. Fatty Acids 85,
381–386.
Shearer, G. C., Pottala, J. V., Spertus,
J. A., and Harris, W. S. (2009).
Red blood cell fatty acid patterns
and acute coronary syndrome. PLoS
ONE 4, e5444. doi:10.1371/jour-
nal.pone.0005444
Shen, J., Johnson, V. M., Sullivan, L. M.,
Jacques, P. F., Magnani, J. W., Lubitz,
S. A., Pandey, S., Levy, D., Vasan, R.
S., Quatromoni, P. A., Junyent, M.,
Frontiers in Physiology | Cardiac Electrophysiology April 2012 | Volume 3 | Article 88 | 10
von Schacky Omega-3’s and cardiac rhythm
Ordovas, J. M., and Benjamin, E. J.
(2011). Dietary factors and incident
atrial ﬁbrillation: the Framingham
Heart Study. Am. J. Clin. Nutr. 93,
261–236.
Skuladottir, G. V., Heidarsdottir, R.,
Arnar, D. O., Torfason, B., Edvards-
son, V., Gottskalksson, G., Palsson,
R., and Indridason, O. S. (2011).
Plasma n-3 and n-6 fatty acids and
the incidence of atrial ﬁbrillation
following coronary artery bypass
graft surgery. Eur. J. Clin. Invest. 41,
995–1003.
Smith, P. J., Blumenthal, J. A., Babyak,
M. A., Georgiades, A., Sherwood,
A., Sketch, M. H. Jr., and Watkins,
L. L. (2009). Association between
n-3 fatty acid consumption and
ventricular ectopy after myocardial
infarction. Am. J. Clin. Nutr. 89,
1315–1320.
Streppel, M. T., Ocké, M. C.,
Boshuizen, H. C., Kok, F. J.,
and Kromhout, D. (2008). Long-
term ﬁsh consumption and n-3 fatty
acid intake in relation to (sudden)
coronary heart disease death: the
Zutphen study. Eur. Heart J. 29,
2024–2030.
Tsuburaya, R.,Yasuda, S., Ito,Y., Shiroto,
T., Gao, J. Y., Ito, K., and Shimokawa,
H. (2011). Eicosapentaenoic acid
reduces ischemic ventricular ﬁbrilla-
tion via altering monophasic action
potential in pigs. J.Mol. Cell. Cardiol.
51, 329–336.
Virtanen, J. K., Mursu, J., Voutilainen,
S., and Tuomainen, T. P. (2009).
Serum long-chain n-3 polyunsatu-
rated fatty acids and risk of hospi-
tal diagnosis of atrial ﬁbrillation in
men. Circulation 120, 2315–2323.
Viviani Anselmi, C., Ferreri, C., Nov-
elli, V., Roncarati, R., Bronzini, R.,
Marchese, G., Somalvico, F., Con-
dorelli, G., Montenero, A. S., and
Puca, A. A. (2010). Fatty acid per-
centage in erythrocyte membranes
of atrial ﬂutter/ﬁbrillation patients
and controls. J. Interv. Card. Electro-
physiol. 27, 95–99.
von Schacky, C. (2008). Omega-3
fatty acids pro-arrhythmic, anti-
arrhythmic or both ? Curr. Opin.
Clin. Nutr. Metab. Care 11, 94–99.
von Schacky, C. (2010). Omega-3 fatty
acids vs. cardiac disease – the con-
tribution of the omega-3 index.
Cell. Mol. Biol. (Noisy-le-grand) 56,
93–101.
von Schacky, C. (2011). The omega-3
index as a risk factor for cardiovas-
cular diseases. Prostaglandins Other
Lipid Mediat. 96, 94–98.
Watanabe, E., Sobue, Y., Sano, K.,
Okuda, K., Yamamoto, M., and
Ozaki, Y. (2011). Eicosapentaenoic
acid for the prevention of recurrent
atrial ﬁbrillation. Ann. Noninvasive
Electrocardiol. 16, 373–378.
Wilhelm, M., Tobias, R., Asskali, F.,
Kraehner, R., Kuly, S., Klingham-
mer, L., Boehles, H., and Daniel, W.
G. (2008). Red blood cell omega-
3 fatty acids and the risk of ven-
tricular arrhythmias in patients with
heart failure. Am. Heart J. 155,
971–977.
Wu, J. H., Lemaitre, R. N., King, I.
B., Song, X., Sacks, F. M., Rimm,
E. B., Heckbert, S. R., Siscov-
ick, D. S., and Mozaffarian, D.
(2012). Association of plasma phos-
pholipid long-chain omega-3 fatty
acids with incident atrial ﬁbrilla-
tion in older adults: the cardiovas-
cular health study. Circulation 125,
1084–1093.
Xiao, Y. F., Sigg, D. C., Ujhelyi, M.
R., Wilhelm, J. J., Richardson, E. S.,
and Iaizzo, P. A. (2008). Pericardial
delivery of omega-3 fatty acid: a
novel approach to reducing myocar-
dial infarct sizes and arrhythmias.
Am. J. Physiol. Heart Circ. Physiol.
294, H2212–H2218.
Yokoyama, M., Origasa, H., Mat-
suzaki, M., Matsuzawa, Y., Saito,
Y., Ishikawa, Y., Oikawa, S., Sasaki,
J., Hishida, H., Itakura, H., Kita,
T., Kitabatake, A., Nakaya, N.,
Sakata, T., Shimada, K., Shirato, K.,
and Japan EPA lipid intervention
study (JELIS) Investigators. (2007).
Effects of eicosapentaenoic acid on
major coronary events in hyperc-
holesterolaemic patients (JELIS):
a randomised open-label, blinded
endpoint analysis. Lancet 369,
1090–1098.
Zeghichi-Hamri, S., de Lorgeril, M.,
Salen, P., Chibane, M., de Leiris,
J., Boucher, F., and Laporte, F.
(2010). Protective effect of dietary
n-3 polyunsaturated fatty acids on
myocardial resistance to ischemia-
reperfusion injury in rats. Nutr. Res.
30, 849–857.
Conﬂict of Interest Statement: In
the last 3 years, the author has
received speaker’s honoraria from
Solvay/Abbott, Pronova, and DSM.
Through the University of Munich,
research was funded by Smartﬁsh and
Sanoﬁ-Aventis. The author has founded
Omegametrix, a company offering fatty
acid analyses.
Received: 19December 2011; accepted: 23
March 2012; published online: 17 April
2012.
Citation: von Schacky C (2012) Omega-
3 fatty acids: anti-arrhythmic, pro-
arrhythmic, or both? Front. Physio. 3:88.
doi: 10.3389/fphys.2012.00088
This article was submitted to Frontiers in
Cardiac Electrophysiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 von Schacky. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org April 2012 | Volume 3 | Article 88 | 11
